A Hydrophilic Interaction Liquid Chromatography–Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Hydrophilic Interaction Liquid Chromatography–Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats
Authors
Keywords
-
Journal
MOLECULES
Volume 25, Issue 7, Pages 1600
Publisher
MDPI AG
Online
2020-04-03
DOI
10.3390/molecules25071600
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials
- (2019) Chengfeng Qiu et al. Lipids in Health and Disease
- Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis
- (2019) Amanda Mogul et al. ANNALS OF PHARMACOTHERAPY
- Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring
- (2019) Dora Koller et al. TALANTA
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
- (2018) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- Efficacy of baricitinib in the treatment of rheumatoid arthritis
- (2017) Christophe Richez et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials
- (2017) Yoshiya Tanaka et al. Modern Rheumatology
- A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro
- (2017) Kohei Murakami et al. PLoS One
- Ocular manifestation of rheumatoid arthritis-different forms and frequency
- (2017) Gordana Zlatanović et al. Bosnian Journal of Basic Medical Sciences
- AB0492 Evaluation of Potential Drug-Drug Interactions with Baricitinib
- (2015) C. Payne et al. ANNALS OF THE RHEUMATIC DISEASES
- Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine
- (2015) Javier Rodríguez-Carrio et al. CLINICAL SCIENCE
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Hydrophilic Interaction Liquid Chromatography and Per Aqueous Liquid Chromatography in Fungicides Analysis
- (2012) Sylwia Noga et al. JOURNAL OF AOAC INTERNATIONAL
- Impact of column temperature and mobile phase components on selectivity of hydrophilic interaction chromatography (HILIC)
- (2008) Zhigang Hao et al. JOURNAL OF SEPARATION SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started